医学
免疫疗法
肺癌
癌基因
生物标志物
靶向治疗
临床试验
CD8型
癌症研究
肿瘤科
癌症
突变
内科学
免疫学
免疫系统
细胞周期
基因
化学
生物化学
作者
Alfredo Addeo,Antonio Passaro,Umberto Malapelle,Giuseppe Luigi Banna,Vivek Subbiah,Alex Friedlaender
标识
DOI:10.1016/j.ctrv.2021.102179
摘要
•The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered and improved the therapeutic landscape of non-small cell lung cancer (NSCLC).•ICIs confer a durable response in a subset of patients; however, their therapeutic role in oncogene-driven NSCLC remains unclear, as the vast majority of trials was conducted without patients harbouring established oncogenic mutations.•The only randomised data available on the efficacy of ICIs on oncogene addicted NSCLC come from the IMpower 150 trial and concern only EGFR mutated NSCLC patients.•At present, no biomarker is clearly predictive for response or benefit to ICIs in oncogene addicted NSCLC. These are often characterised by low tumour mutation burden (TMB) and a less inflammatory tumour microenvironment, poor in tumour-infiltrating CD8+ lymphocytes. PD-L1 can be constitutionally overexpressed without having any clinical significance.
科研通智能强力驱动
Strongly Powered by AbleSci AI